Increased m(6)A modification of lncRNA DBH-AS1 suppresses pancreatic cancer growth and gemcitabine resistance via the miR-3163/USP44 axis

BACKGROUND: Gemcitabine is among the most commonly utilized chemotherapeutic agents for treating pancreatic cancer (PC), yet patients ultimately develop chemoresistance and thus exhibit a poor prognosis. Long noncoding RNAs (lncRNAs) can function as key regulators of PC progression and may serve as...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Xin, Wang, Li-Ping, Han, Cong, Hu, Hao, Ni, Chen-Ming, Qiao, Guang-Lei, Ouyang, Liu, Ni, Jun-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011309/
https://www.ncbi.nlm.nih.gov/pubmed/35433957
http://dx.doi.org/10.21037/atm-22-556

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011309/
https://www.ncbi.nlm.nih.gov/pubmed/35433957
http://dx.doi.org/10.21037/atm-22-556

Ejemplares similares